nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2011 | Editorial Commentary

Towards new horizons in brain PET

verfasst von: Marco Pagani

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Excerpt

There is an increasing need in routine clinical neuroimaging for simple and accessible methodologies which can reduce examination times but still provide reliable information about the status of the disease. More widespread use of PET technology would be favoured by avoiding the investment and running expenses associated with an on-site cyclotron. The clinical implementation of PET would benefit from cost reductions. The use of isotope generators could potentially allow centres remote from a cyclotron to have access to a wide range of radiopharmaceuticals. …

Yagi M, Kondo KA. 62Cu generator. Int J Appl Radiat Isot. 1979;30:569–70.CrossRef

Robinson GD, Zielinski FW, Lee AW. The zinc-62/copper-62 generator: a convenient source of copper-62 for radiopharmaceuticals. Int J Appl Radiat Isot. 1980;31:111–16.PubMedCrossRef

Fujibayashi Y, Matsumoto K, Yonekura Y, Konishi J, Yokoyama A. A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals. J Nucl Med. 1989;30:1838–42.PubMed

Haynes NG, Lacy JL, Nayak N, Martin CS, Dai D, Mathias CJ, et al. Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM. J Nucl Med. 2000;41:309–14.PubMed

Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med. 2009;50:1948–53.PubMedCrossRef

Ikawa M, Okazawa H, Arakawa K, Kudo T, Kimura H, Fujibayashi Y, et al. PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion. 2009;9:144–8.PubMedCrossRef

Wallhaus TR, Lacy J, Whang J, Green MA, Nickles RJ, Stone CK. Human biodistribution and dosimetry of the PET perfusion agent copper-62-PTSM. J Nucl Med. 1998;39:1958–64.PubMed

Isozaki M, Kiyono Y, Arai Y, Kudo T, Mori T, Maruyama R, et al. Feasibility of 62Cu-ATSM PET for evaluation of brain ischaemia and misery perfusion in patients with cerebrovascular disease. Eur J Nucl Med Mol Imaging. 2011. doi:10.1007/00259-011-1734-z.PubMed

Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–60.PubMed

10.

Okazawa H, Kudo T. Clinical impact of hemodynamic parameter measurement for cerebrovascular disease using positron emission tomography and 15O-labeled tracers. Ann Nucl Med. 2009;23:217–27.PubMedCrossRef

11.

Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177–83.PubMed

12.

Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001;42:655–61.PubMed

13.

Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol. 2005;32:623–30.PubMedCrossRef

14.

Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49:129S–48S.PubMedCrossRef

15.

Wong TZ, Lacy JL, Petry NA, Hawk TC, Sporn TA, Dewhirst MW, et al. PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator. AJR Am J Roentgenol. 2008;190:427–32.PubMedCrossRef

16.

Holland JP, Lewis JS, Dehdashti F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging. 2009;53:193–200.PubMed

17.

Mees G, Dierckx R, Vangestel C, Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging. 2009;36:1674–86.PubMedCrossRef

18.

Fujibayashi Y, Wada K, Taniuchi H, Yonekura Y, Konishi J, Yokoyama A. Mitochondria-selective reduction of 62Cu-pyruvaldehyde bis(N4-methylthiosemicarbazone) (62Cu-PTSM) in the murine brain; a novel radiopharmaceutical for brain positron emission tomography (PET) imaging. Biol Pharm Bull. 1993;16:146–9.PubMed

19.

Taniuchi H, Fujibayashi Y, Okazawa H, Yonekura Y, Konishi J, Yokoyama A. Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM), a metal complex with selective NADH-dependent reduction by complex I in brain mitochondria: a potential radiopharmaceutical for mitochondria-functional imaging with positron emission tomography (PET). Biol Pharm Bull. 1995;18:1126–9.PubMed

20.

Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem. 2002;7:249–59.PubMedCrossRef

21.

Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GE. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem. 2002;45:1420–31.PubMedCrossRef

22.

Dearling JL, Packard AB. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol. 2010;37:237–43.PubMedCrossRef

23.

Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, et al. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG. Nucl Med Biol. 2003;30:529–34.PubMedCrossRef

24.

Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Waki A, Mori T, et al. Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma. Nucl Med Biol. 2010;37:395–404.PubMedCrossRef

25.

Dence CS, Ponde DE, Welch MJ, Lewis JS. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 2008;35:713–20.PubMedCrossRef

Titel: Towards new horizons in brain PET
verfasst von: Marco Pagani
Publikationsdatum: 01.06.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2011
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1813-1

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2011

Functional imaging in head and neck squamous cell carcinoma: correlation of PET/CT and diffusion-weighted imaging at 3 Tesla

PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma

In vivo positron emission tomography imaging with [11C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons

Focus on time-of-flight PET: the benefits of improved time resolution

Vascular time-activity variation in patients undergoing 123I-MIBG myocardial scintigraphy: implications for quantification of cardiac and mediastinal uptake

The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease